This 2020 electron microscope image provided by the National Institute of Allergy and Infectious Diseases - Rocky Mountain Laboratories shows SARS-CoV-2 virus particles which cause COVID-19, isolated from a patient in the U.S., emerging from the surface of cells cultured in a lab. According to a study released in The Lancet Global Health on Wednesday, Oct. 27, 2021, Fluvoxamine, a cheap antidepressant, reduced the need for hospitalization among high-risk adults with COVID-19. (NIAID-RML via AP)
By Carla K. Johnson
A cheap antidepressant reduced the need for hospitalization among high-risk adults with COVID-19 in a study hunting for existing drugs that could be repurposed to treat coronavirus.
Researchers tested the pill used for depression and obsessive-compulsive disorder because it was known to reduce inflammation and looked promising in smaller studies.
They've shared the results with the U.S. National Institutes of Health, which publishes treatment guidelines, and they hope for a World Health Organization recommendation.
“If WHO recommends this, you will see it widely taken up,” said study co-author Dr. Edward Mills of McMaster University in Hamilton, Ontario, adding that many poor nations have the drug readily available. “We hope it will lead to a lot of lives saved.”
The pill, called fluvoxamine, would cost $4 for a course of COVID-19 treatment. By comparison, antibody IV treatments cost about $2,000 and Merck's experimental antiviral pill for COVID-19 is about $700 per course. Some experts predict various treatments eventually will be used in combination to fight the coronavirus.
Researchers tested the antidepressant in nearly 1,500 Brazilians recently infected with coronavirus who were at risk of severe illness because of other health problems, such as diabetes. About half took the antidepressant at home for 10 days, the rest got dummy pills. They were tracked for four weeks to see who landed in the hospital or spent extended time in an emergency room when hospitals were full.
In the group that took the drug, 11% needed hospitalization or an extended ER stay, compared to 16% of those on dummy pills.
The results, published Wednesday in the journal Lancet Global Health, were so strong that independent experts monitoring the study recommended stopping it early because the results were clear.
Questions remain about the best dosing, whether lower risk patients might also benefit and whether the pill should be combined with other treatments.
The larger project looked at eight existing drugs to see if they could work against the pandemic virus. The project is still testing a hepatitis drug, but all the others — including metformin, hydroxychloroquine and ivermectin — haven't panned out.
The cheap generic and Merck's COVID-19 pill work in different ways and “may be complementary,” said Dr. Paul Sax of Brigham and Women’s Hospital and Harvard Medical School, who was not involved in the study. Earlier this month, Merck asked regulators in the U.S. and Europe to authorize its antiviral pill.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.
Brightseed Co-Founder Sofia Elizondo breaks down what plant bioactives are, and how they're using the latest technology to study human's biological connections with plants.
On this episode of Cheddar Innovates: Brightseed Co-Founder breaks down what plant bioactives are, and how they're using the latest technology to study human's biological connections with plants; Esper Bionics CEO breaks down how they re creating a mind-controlled bionic hand that guest smarter the more you use it; Cheddar gets a look at Curiosity Stream's 'Capturing A Black Hole In Our Milky Way.'
Hilary Kearney, Founder of Girl Next Door Honey, joined Closing Bell to discuss her partnership with Comvita to save the important pollinators, as bee colonies are on the decline across the United States.
Hurricane climatologist Jill Trepanier joined Cheddar News to discuss NOAA's announced prediction for an above-normal hurricane season and what it might mean for people in the United States. "I think it's important that people who maybe haven't been used to having extreme weather events related to say tropical cycles and tropical systems, like thinking New Jersey, Northeastern seaboard, that area may get more action than they're used to in the past," she said.
Dr. Jarrad Aguirre, Co-Founder and CEO of Miga Health, joins Cheddar News' Closing Bell, where he says his company is looking to establish the future of heart health and points to how 80% of premature heart attacks and strokes are preventable.
On this episode of Cheddar Reveals, David Keith, Professor of Applied Physics at the Harvard School of Engineering and Applied Sciences and Professor of Public Policy at the Harvard Kennedy School, and founder of Carbon Engineering outlines the viability of solar geoengineering as a solution to help reverse the effects of global warming; Lena Geraghty, Sustainability & Urban Innovation Director at National League of Cities, discusses which U.S. cities are safest from global warming and how the real estate market will be impacted from the effects of climate change; Cheddar gets a look at Curiosity Stream's 'Changing Ocean Asia.'
David Keith, Professor of Applied Physics at the Harvard School of Engineering and Applied Sciences and Professor of Public Policy at the Harvard Kennedy School, and founder of Carbon Engineering joins Cheddar Reveals to outline the viability of solar geoengineering as a solution to help reverse the effects of global warming.
Lena Geraghty, Sustainability & Urban Innovation Director at National League of Cities, joins Cheddar News to discuss which U.S. cities are safest from global warming and how the real estate market will be impacted from the effects of climate change.
Peggy Whitson, Director of Human Space Flight, Axiom Space, joins Cheddar Innovates to discuss Axiom's involvement in the first fully-private mission to the ISS, and her experience spending 665 days in space.
On this episode of Cheddar Innovates, Peggy Whitson, Director of Human Space Flight, Axiom Space, breaks down Axiom's involvement in the first fully-private mission to the ISS, and her experience spending 665 days in space; William Li and Danielle Chang, co-founders of The Hao Life, discuss how they're shaking up the $71 billion supplement industry by putting a modern spin on traditional natural Chinese remedies; Cheddar gets a look at Curiosity Stream's 'Sagrada Familia: Gaudi's Challenge.'
